Prothena | PRTA - Gross Profit On Sales


Prothena reported $51.08M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
ALKERMES USD 375.31M 43.98M Jun/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
Biogen USD 2.12B 307M Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Exelixis USD 608.03M 17.17M Jun/2026
Immunic 0 0 Mar/2025
Incyte USD 1.57B 400.89M Jun/2026
Ionis Pharmaceuticals USD 265M 22M Jun/2026
MacroGenics USD 11.24M 19.87M Mar/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Prothena USD 51.08M 51.06M Mar/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026